Prognostic factors of all-cause mortalities in continuous ambulatory peritoneal dialysis: a cohort study by Phisitt Vejakama et al.
Vejakama et al. BMC Nephrology 2013, 14:28
http://www.biomedcentral.com/1471-2369/14/28RESEARCH ARTICLE Open AccessPrognostic factors of all-cause mortalities in
continuous ambulatory peritoneal dialysis:
a cohort study
Phisitt Vejakama1,2, Ammarin Thakkinstian1*, Atiporn Ingsathit1, Prateep Dhanakijcharoen3 and John Attia4Abstract
Background: The role of small solute clearance on mortalities in patients with CAPD has been controversial. We
therefore conducted a study with 3 years' follow up in adult patients who participated in the CAPD-first policy.
Methods: There were 11,523 patients with end-stage renal disease who participated in the CAPD-first policy
between 2008 and 2011. Among them, 1,177 patients were included in the retrospective cohort study. A receiver
operating characteristic curve was applied to calibrate the cutoffs of tKt/V, rKt/V and tCrcl. Kaplan-Meier and
Cox-regression models with time varying covariates were applied to estimate overall death rate, probability of
death and prognosis, respectively.
Results: The cutoffs of rKt/V and tKt/V were 0.25 and 1.75, respectively. The Cox regression suggested that the
higher these clearance parameters, the lower the risks of death after adjusting for covariables. The risks of death for
those above these cutoffs were 57% (HR = 0.43, 95% CI: 0.31, 0.60) and 29% (HR = 0.71, 95% CI: 0.52, 0.98) lower for
rKt/V and tKt/V, respectively. Age, serum albumin, hemoglobin, systolic blood pressure, and ultra-filtration volume
significantly affected the mortality outcome.
Conclusions: Our study suggested that the cutoffs of 0.25 and 1.75 for rKt/V and tKt/V might be associated with
mortality in CAPD patients. A minimum tKt/V of 1.75 should be targeted, but increased dialysis dosage to achieve
tKt/V > 2.19 adds no further benefit. Serum albumin, hemoglobin, SBP, and UF volume are also associated with
mortality. However, our study may face with selection and other unobserved confounders, so further randomized
controlled trials are required to confirm these cutoffs.
Keywords: Adequacy indices, CAPD, Continuous ambulatory peritoneal dialysis, Mortality, Peritoneal small solute
clearance, Prognostic factorsBackground
The global burden of end-stage kidney disease (ESRD) is
increasing rapidly [1-3] with a prevalence of 0.2% in the
USA, and 0.3% in Thailand respectively [4,5]. Renal re-
placement therapy (i.e., renal transplantation or dialysis)
is required for ESRD patients, and 2 modalities, hemo-
dialysis and continuous ambulatory peritoneal dialysis
(CAPD), have been widely used. The numbers of
patients on CAPD has been growing rapidly in Asian
countries, representing about 80% of dialysis patients in* Correspondence: ammarin.tha@mahidol.ac.th
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reproduction in any medium, provided the orHong Kong, and 50% in Thailand in 2011. A health care
reform scheme for all Thai citizens, called the “Universal
Coverage” scheme (UC) was first initiated in 2002, and it
has covered renal replacement therapy for CAPD-first
treatment since 2008. The usage of four 2-L daily
exchanges with double-bag disconnected systems has
been a standard CAPD regime in Thailand.
Adequacy targets for CAPD are primarily based on the
weekly clearances of urea (Kt/V) or creatinine (Crcl)
which are expressed as renal Kt/V (rKt/V), peritoneal
Kt/V (pKt/V), total Kt/V (tKt/V); or renal Crcl (rCrcl),
peritoneal Crcl (pCrcl), and total Crcl (tCrcl) respect-
ively. The effect of rKt/V on survival in CAPD patients
has been well-documented [6-14], but the roles of pKt/V,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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found that higher pKt/V and/or tKt/V were associated
with longer survival times, whereas some observational
studies [6-8,10-12] and randomized controlled trials
[13,14] did not find such associations. Many factors may
affect these outcomes, such as dialysis dosage, residual
renal function, power of test, cutoff threshold used, and
follow-up period.
We therefore conducted a cohort study with 3 years’
follow up to answer the following research questions:
Can tKt/V, rKt/V, and tCrcl significantly predict disease
prognosis in CAPD patients? If so, what are the cutoffs
that can be used to predict patients’ outcomes?
Methods
Setting & participants
This cohort study covered patients receiving four 2-L
CAPD exchanges at 82 general hospitals, belonging to
the Ministry of Public Health, Thailand. Data from the
National Health Security Office (NHSO) were retrieved
between January 2008 and April 2011. The study was
approved by the Ramathibodi Hospital Ethical Committees.
Patients aged 15 years or older were eligible if they met
the following criteria: Firstly initiated CAPD and partici-
pated in the CAPD first-policy from January 2008 to April
2011, survived more than 1 month after initiating CAPD,
and had at least 1tKt/V during the studied period.
Patients were ineligible if they had the following criteria:
on CAPD due to acute renal failure, aged > 100 years,
tKt/V < 0.5 or > 5, tCrcl < 10 or > 400 L/week/1.73 m2,
serum albumin level < 0.3 or > 6 g/dl, hemoglobin level
< 3 or > 20 g/dl, urine volume < 0 or > 4,000 ml, ultra-
filtration (UF) volume < −2,000 or > 4,000 ml, systolic
blood pressure (SBP) < 40 or > 300 mmHg, or diastolic
blood pressure (DBP) < 10 or > 200 mmHg.
Clinical endpoint
The primary outcome of the study was time since first ini-
tiation of CAPD therapy to death. Patients were censored
if they were lost to follow up, or survived at the end of the
study (May 2011). Death referred to all cause mortality
and the data were validated by cross-referencing with the
death certificate database from the Ministry of the Interior.
Prognostic factors
The studied prognostic factors were renal (i.e., rKt/V and
rCrcl) and peritoneal (i.e., pKt/V and pCrcl) small solute
clearances. The former clearance was estimated using a
ratio of concurrent urea/creatinine excretion in 24-hour
urine whereas the latter clearance was estimated using
24-hour dialysate effluent. The total small solute clearance
(e.g., tKt/V or tCrcl) was the summation of renal and peri-
toneal small solute clearance. Urea distribution volume
(V) was measured using Watson's formula [16].These small solute clearances (i.e., rKt/V, tKt/V, tCrcl)
and other variables were considered in the prognostic
model, which included age, gender, body mass index
(BMI), serum albumin, hemoglobin, UF volume, SBP,
DBP, and co-morbidities (i.e., diabetes, hypertension
and/or cardio-vascular disease (CVD)). Among these
variables, tKt/V, rKt/V, tCrcl, BMI, serum albumin,
hemoglobin, UF volume, SBP, and DBP were considered
in the analysis as time-varying covariates, whereas the
rest were fixed variables.Statistical analyses
Imputation
Among 1,177 eligible patients, the data for UF volume,
hemoglobin, serum albumin, rKt/V, BMI, tCrcl, and co-
morbidities were missing in 0.3%, 1.1%, 3.3%, 6.5%,
11.5%, 16.7%, and 36.3% of patients, respectively. For
each patient, the last observed value was carried forward
to replace missing data. Then, the rest of the missing
data were imputed using multivariate chain equations. A
simulation-based procedure [17,18] with the assumption
that data were missing at random was applied. Logistic
and linear regressions were applied to predict missing
data for dichotomous and continuous data, respectively.
Twenty imputations were performed to allow for the un-
certainty of imputed data and the summarized values
were then used [19].Calibration of the cutoff threshold
The received operative characteristic (ROC) curve was
used to determine the cutoff of tKt/V, rKt/V, and tCrcl
that could discriminate death from living patients. Each
variable was fitted in the ROC model as both continuous
and categorized variables, separately. For categorical vari-
ables, they were categorized according to tertile distribu-
tions. The likelihood ratio positive (LR+) and Youden’s
index (i.e., highest sensitivity + specificity −1) [20] were
then used to select the cutoff threshold. The performance
of the cutoff thresholds suggested by the two methods
were incorporated which led to the final cutoffs.
Kaplan-Meier was applied to estimate the overall death
rate and probability of death at 12-, 24-, and 36- months
after first-initiated CAPD. A patient was censored if s/he
had one of the following events: loss to follow-up, with-
drew from the CAPD program, or alive at the end of fol-
low up period. Cox-regression models with time varying
covariates were applied to assess prognostic effects by
fitting equations that separately contained rKt/V and
tKt/V. Prognostic scores were then calculated from the
final Cox models. The ROC curve analysis was used to
estimate the area under the ROC curves (AUC) between
the two prognostic scores [21].
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12. The p-value of less than 0.05 was considered statisti-
cally significant.
Results
We identified 11,523 patients in the CAPD registry and
follow-up databases from January 2008 to May 2011.
Among them, 11,352 patients were aged 15 years or
older, but only 1,188 (10.5%) patients had at least one
tKt/V data. Eleven patients had a tKt/V out of the ac-
ceptable range (i.e., tKt/V < 0.5 or > 5) and thus they
were excluded, leaving 1,177 patients with 23,144 obser-
vations for the primary analysis, see Figure 1. Baseline
characteristics of eligible versus ineligible subjects were
compared which found that eligible patients were
younger (50 vs. 53, p <0.001), had slightly higher propor-
tions of anuria (5.4% vs. 2.9%, p < 0.001), serum albumin
(3.3 vs. 3.2, p < 0.001); higher mean hemoglobin (9.0 vs.
8.8, p < 0.001), urine output (704 vs. 645 ml, p < 0.001),
and diastolic blood pressure (81 vs 80, p = 0.021) than
ineligible patients. However, both groups had similar
proportions of males (50.1% vs. 48.4%, p = 0.26, diabetes
(33.2% vs. 30.5%, p = 0.12), hypertension (39.2% vs.
36.0%, p = 0.08), cardiovascular disease (4.4 vs. 3.1 years,
p = 0.06), and mean SBP (141 vs. 141 mmHg, p = 0.99),















Figure 1 Flow of study design.Calibration of tKt/V, rKt/V and tCrcl cutoff
Data for the tKt/V were categorized as < 1.75 (n = 384),
1.75-2.19 (n = 384), and > 2.19 (n = 409) using a tertile
distribution. Fitting a continuous tKt/V in the ROC
curve analysis yielded an optimum cutoff based on You-
den’s index of 1.65. Sensitivity, specificity, and LR+ of
this cutoff were 0.40, 0.74, and 1.50, respectively. Fitting
a categorical tKt/V in the ROC analysis suggested that a
cutoff of 1.75 yielded sensitivity, specificity, and LR+ of
0.45, 0.65, and 1.31, respectively. The AUCs were similar
for both variables, i.e., 0.556 (95% CI: 0.544, 0.568) vs.
0.551 (95% CI: 0.540, 0.562), respectively. The final cut-
off of 1.75 was chosen because it provided higher
sensitivity.
Fitting rKt/V as a continuous variable in the ROC ana-
lysis resulted in an AUC of 0.632 (95% CI: 0.620, 0.643).
Applying Youden’s index suggested the cutoff of 0.15
with sensitivity, specificity, and LR+ of 0.45, 0.77, and
1.96, respectively. The rKt/V was categorized into 3
groups according to a tertile distribution, i.e., < 0.25,
0.25-0.49, and > 0.49; fitting this categorical variable
yielded the AUC of 0.612 (95% CI: 0.602, 0.623). Al-
though this cutoff yielded slightly inferior performance
(i.e., sensitivity, specificity, and LR+ of 0.53, 0.66, and 1.57
respectively), this rKt/V cutoff of 0.25 was chosen for
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Table 1 Comparisons of baseline characteristics of eligible versus ineligible patients
Variables Eligible group Ineligible group p-value
n No (%)* n No (%)*
Age, year 1,177 50 (14) 10,346 53 (15) < 0.001
Male 1,177 590 (50.1) 10,346 5,008 (48.4) 0.26
£ BMI, kg/m2 1,037 22.4 (4.0) 5,886 22.1 (4.0) 0.09
Serum creatinine, mg/dL 1,177 6.8 (1.1) 10,346 6.8 (1.1) 0.99
Co-morbidities
§ DM 749 249 (33.2) 6,806 2,076 (30.5) 0.12
π HT 749 294 (39.2) 6,806 2,447 (36.0) 0.08
¥ CVD 749 33 (4.4) 6,806 211 (3.1) 0.06
Anuria, N (%) 1,177 63 (5.4) 10,346 311 (2.9) < 0.001
Serum albumin, g/dL 1,138 3.3 (0.7) 8,309 3.2 (0.7) < 0.001
Hemoglobin, g/dL 1,164 9.0 (2.0) 8,572 8.8 (1.9) < 0.001
Urine volume, ml 1,154 705 (529) 9,234 645 (475) < 0.001
μSBP, mmHg 1,177 141 (25) 10,346 141 (26) 0.99
¶DBP, mmHg 1,177 81 (14) 10,346 80 (15) 0.021
*mean (SD) for continuous data, £ Body mass index, § Diabetes, π Hypertension, ¥ Cardiovascular disease, μ Systolic blood pressure, ¶ Diastolic blood pressure,
Conversion factors for units: serum creatinine in mg/dL to mol/L, ×88.4; serum albumin in g/dL to g/L, ×10; hemoglobin in mg/dL to g/L, ×10.
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tween dead and surviving patients with the AUCs of
0.519 (95% CI: 0.506, 0.533) and 0.513 (95% CI: 0.501,
0.525) for continuous and categorical variables,
respectively.
Prognostic factors of death
Among 1,177 patients, the person-time at risk was
21,831 patient-months with a median follow-up of 22.9
months (range: 1.8–43.5 months). One-hundred and
eighty eight patients died which resulted in an overall
death rate of 9.9 (95% CI: 8.6, 11.4) per 100 patient-
years. The probabilities of death at 12-, 24- and 36-
months were 6.7% (95% CI: 5.3%, 8.4%), 19.4% (95% CI:
16.7%, 22.4%) and 29.2% (95% CI: 24.7%, 34.4%),
respectively.
Kaplan-Meier curves were plotted by tKt/V groups
(see Figure 2a). This suggested that the failure curves of
tKt/V of 1.75–2.19 and > 2.19 groups were similar, but
they were lower when compared with tKt/V < 1.75. The
overall death rates were 1.03 (95% CI: 0.83, 1.29), 0.72
(95% CI: 0.56, 0.94), and 0.71 (95% CI: 0.54, 0.92) per
100 patient-months for tKt/V < 1.75, 1.75-2.19, and >
2.19 respectively, see Table 2. The unadjusted hazard
ratios (HRs) were 0.70 (95% CI: 0.49, 0.98), and 0.70
(95% CI: 0.50, 0.99) for tKt/V 1.75–2.19, and > 2.19 when
compared to tKt/V < 1.75, respectively. These two tKt/V
groups were then combined because their HRs were
similar.
The estimated probability of death was decreased as
the rKt/V increased (see Figure 2b). The estimated deathrates were 1.65 (95% CI: 1.35, 2.01), 1.06 (95% CI: 0.80,
1.40), and 0.59 (95% CI: 0.41, 0.85) per 100 patient-
months for rKt/V of < 0.25, 0.25-0.49, and > 0.49, re-
spectively. The unadjusted HRs were 0.64 (95% CI: 0.45,
0.91), and 0.36 (95% CI: 0.23, 0.54) for the groups with
rKt/V of 0.25-0.49 and > 0.49 when compared with the
reference group of < 0.25, respectively. Other covariables
with p-value < 0.25 in the univariate analysis were age,
BMI, serum albumin, hemoglobin, UF volume, SBP, and
diabetes (see Table 2).
After adjusting for covariables, patients with tKt/V
1.75 or higher had 29% (HR = 0.71 (95% CI: 0.52, 0.98)
significantly lower risk of death than patients with tKt/
V < 1.75 (see Table 3). The effects of rKt/V on death
were stronger than tKt/V, with HRs of 0.56 (95% CI:
0.38, 0.80) and 0.30 (95% CI: 0.19, 0.47) for rKt/V 0.25-
0.49 and > 0.49, respectively. This suggested higher rKt/
V gave lower risk of death, i.e., patients with rKt/V 0.25-
0.49 and > 0.49 had approximately 44% and 70% lower
risk of death when compared to patients with rKt/V
lower than 0.25. We further created predictions scores
from model 1 and model 2 (see Table 3). Fitting these
scores in the ROC curve analysis yielded the AUCs of
0.726 (95% CI: 0.716, 0.736) and 0.753 (95% CI: 0.743,
0.763) for model 1 and model 2, respectively; indicating
rKt/V was a better prognostic factor of death than tKt/V.
Age, serum albumin, hemoglobin, UF volume, and SBP
were also significant prognostic factors of death in both
tKt/V and rKt/V models, but BMI and diabetes were sig-
nificant only in the tKt/V model. Patients aged 45–54 and
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Figure 2 Kaplan Meier curves of death by tKt/V, and rKt/V.
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than patients aged younger than 45 years. High serum al-
bumin resulted in better prognosis with 52% (HR = 0.48,
95% CI: 0.34, 0.70), and 75% (HR = 0.25, 95% CI: 0.16,
0.40) lower risk of death for serum albumin 3.0–3.4 g/dl
and > 3.4 g/dl respectively, when compared to albumin
below 3.0 g/dl.
Hemoglobin showed an inverse dose–response relation-
ship with death; those with hemoglobin levels of 9.0-10.9
and > 10.9 g/dl had 32% (HR = 0.68, 95% CI: 0.47, 0.97)
and 56% (HR = 0.44, 95% CI: 0.28, 0.69) respectively
significantly lower risk of death than those with a
hemoglobin level below 9.0 g/dl. UF volume 1,000 ml per
day or higher reduced the risk of death by 47% (HR = 0.53,
95% CI: 0.37, 0.76). Patients whose SBP were 140 mmHg
or higher had 31% (HR = 0.69, 95% CI: 0.51, 0.94) signifi-
cantly lower risk of death than those whose SBP were
below 140 mmHg.
Higher BMI were associated with lower mortality with
the adjusted HR of 0.73 (95% CI: 0.53, 1.04) for BMI 21
kg/m2 or higher when compared with BMI less than 21
kg/m2, but this was not statistically significant. The pres-
ence of diabetes increased the risk of death by 43% withthe adjusted HR of 1.43 (95% CI: 0.98, 2.09), but this
was also not statistically significant.
After adjusting for covariables, patients with tCrcl ≥ 50
L/wk/m2 had 20% (HR = 0.80, 95% CI: 0.56, 1.13) lower
risk of death than patients with tCrcl < 50 L/wk/m2; al-
though this was not statistically significant, data have
not been shown.
Discussion
We conducted a retrospective cohort study of first-
initiated CAPD patients with a median follow-up time of
22.9 months. The 12-, 24- and 36-months probabilities
of death were 6.7% (95% CI: 5.3%, 8.4%), 19.4% (95% CI:
16.7%, 22.4%), and 29.2% (95% CI: 24.7%, 34.4%), re-
spectively with the overall death rate of 9.9 (95% CI: 8.6,
11.4) per 100 patient-years. Prognostic factors of death
were explored suggesting that rKt/V was the strongest
predictor of death followed by tKt/V. The cutoff thresh-
olds of these parameters that discriminated poor from
good prognosis were ≥ 0.25 for rKt/V and ≥ 1.75 for tKt/V.
Patients with the rKt/V and tKt/V higher than the cutoffs
had respectively 65% and 29% lower risk of death than
patients with lower levels than the cutoffs.
Table 2 Described death rates and HR according to







< 1.75 1.03 (0.83, 1.29) 1
1.75–2.19 0.72 (0.56, 0.94) 0.70 (0.49, 0.98) 0.04
> 2.19 0.71 (0.54, 0.92) 0.70 (0.50, 0.99) 0.04
rKt/V
< 0.25 1.65 (1.35, 2.01) 1
0.25–0.49 1.06 (0.80, 1.40) 0.64 (0.45, 0.91) 0.01
> 0.49 0.59 (0.41, 0.85) 0.36 (0.23, 0.54) < 0.001
tCrcl, ml/week/
1.73 m2
< 50 0.88 (0.66, 1.16) 1
50–64 0.66 (0.50, 0.87) 0.74 (0.50, 1.10) 0.14
> 64 0.78 (0.59, 1.03) 0.93 (0.63, 1.39) 0.73
Age, years
< 45 0.52 (0.39, 0.70) 1
45–54 0.81 (0.61, 1.07) 1.64 (1.09, 2.47) 0.02
> 54 1.12 (0.92, 1.37) 2.41 (1.68, 3.44) < 0.001
Gender
Female 0.83 (0.68, 1.01) 1
Male 0.81 (0.66, 0.99) 0.96 (0.72, 1.28) 0.80
£ BMI, kg/m2
< 21.0 0.91 (0.71, 1.16) 1
21.0 – 23.9 0.77 (0.58, 1.01) 0.78 (0.54, 1.13) 0.19
> 23.9 0.77 (0.59, 1.01) 0.71 (0.54, 1.11) 0.16
Serum albumin,
g/dL
< 3.0 1.72 (1.41, 2.10) 1
3.0–3.4 0.76 (0.57, 0.99) 0.41 (0.29, 0.57) < 0.001
> 3.4 0.37 (0.27, 0.50) 0.20 (0.13, 0.29) < 0.001
Hemoglobin, g/
dL
< 9.0 1.08 (0.86, 1.36) 1
9.0–10.9 0.84 (0.68, 1.05) 0.67 (0.48, 0.92) 0.01
> 10.9 0.49 (0.35, 0.68) 0.38 (0.25, 0.57) < 0.001
§ UF volume, ml
< 500 0.89 (0.66, 1.18) 1
500–999 0.93 (0.75, 1.15) 0.93 (0.65, 1.33) 0.69
> 999 0.64 (0.50, 0.84) 0.59 (0.40, 0.87) 0.01
μ SBP, mmHg
< 140 0.91 (0.75, 1.11) 1
≥ 140 0.74 (0.60, 0.90) 0.83 (0.62, 1.10) 0.19
¶ DBP, mmHg
< 90 0.85 (0.71, 1.01) 1
≥ 90 0.76 (0.59, 98) 0.92 (0.67, 1.24) 0.57
Table 2 Described death rates and HR according to
prognostic factors: a univariate analysis (Continued)
Diabetes
Yes 1.19 (0.95, 1.49) 1.74 (1.27, 2.38) 0.001
No 0.67 (0.56, 0.81) 1
Hypertension
Yes 0.85 (0.69, 1.04) 1.06 (0.75, 1.49) 0.74
No 0.79 (0.65, 0.97) 1
¥ CVD
Yes 0.82 (0.49, 1.38) 0.92 (0.48, 1.78) 0.81
No 0.82 (0.71, 0.95) 1
θ Confidence Interval, ᴚ Hazards Ratio £ Body mass index, § Ultra-filtration, μ
Systolic blood pressure, ¶ Diastolic blood pressure, ¥ Cardiovascular disease,
Conversion factors for units: serum albumin in g/dL to g/L, ×10; hemoglobin in
mg/dL to g/L, ×10.
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6.7% and 19.4% for 1- and 2-year probabilities of death)
when compared with the mortality rates in other Asian
countries, e.g., Indian (20% and 40% ) [22], and China
(10% and 21%) [23]. This might be explained by our
study included patients who were firstly initiated CAPD
while those studies included both prevalent and incident
CAPD cases. Modalities of CAPD exchanges were differ-
ent, we used four 2-L CAPD exchanges whereas those
studied used three 2-L CAPD exchanges. Although our
study had higher prevalence of diabetes compared with
the Chinese study [19], our patients were younger (mean
age 50 vs. 54 years) and about three times lower CVD
(4.4% vs. 14.2%) than the Chinese study. We included
only patients who had tKt/V data and survived at least 1
month after first-initiated CAPD. As such, our mortality
rate was lower than previous studies.
Unlike rKt/V, the roles of tKt/V on mortality has not
been consistently demonstrated by previous studies
[6,7,12-14,20-24]. Although there was a trend in favor of
higher tKt/V, those studies could not demonstrate statis-
tical significance [6,7,12-14,24], but our study had suffi-
cient power to detect this association. However, the
prognostic effect of tKt/V needs to be confirmed by
further studies since its effect was borderline significant.
A target small solute clearance has long been a critical
issue. Since increasing the peritoneal dialysis prescrip-
tion may increase the patients' discomfort, decrease the
quality of life, and harm by metabolic glucose load, the
advantages from increased dialysis dose and potential
harms should be well-balanced. Unfortunately, the
optimum target clearance has not been well-formulated
due to lack of previous evidence and our study should
be able to fill information for this issue. Both continuous
and categorical variables for small solute clearances were
explored in the ROC curve analyses and suggested the
optimum cutoffs for tKt/V and rKt/V. These cutoffs
Table 3 Cox proportional hazards model for all-cause mortalities using tKt/V and rKt/V as prognostic factors
Model 1: tKt/V Model 2: rKt/V
Variables Coefficient SEӔ HRᴚ (95% CIθ) p–value Coefficient SE HR (95% CI) p–value
tKt/V
< 1.75 1
≥ 1.75 −0.34 0.11 0.71 (0.52, 0.98) 0.04
rKt/V
< 0.25 1
0.25-0.49 −0.59 0.11 0.56 (0.38, 0.80) 0.00
> 0.49 −1.22 0.07 0.30 (0.19, 0.47) < 0.001
Age, year
< 45 1 1
45 – 54 0.59 0.44 1.81 (1.12, 2.92) 0.02 0.64 0.46 1.89 (1.17, 3.04) 0.01
> 54 0.89 0.51 2.44 (1.61, 3.69) < 0.001 0.99 0.59 2.70 (1.77, 4.13) < 0.001
£BMI, kg/m2
< 21 1 1
≥ 21 −0.37 0.12 0.69 (0.50, 0.96) 0.03 −0.30 0.13 0.73 (0.53, 1.04) 0.08
Serum albumin, g/
dL
< 3.0 1 1
3.0–3.4 −0.74 0.09 0.48 (0.33, 0.68) < 0.001 −0.73 0.09 0.48 (0.34, 0.70) < 0.001
> 3.4 −1.42 0.05 0.24 (0.16, 0.37) < 0.001 −1.39 0.06 0.25 (0.16, 0.40) < 0.001
Hemoglobin, g/dL
< 9.0 1 1
9.0–10.9 −0.36 0.12 0.70 (0.49, 0.98) 0.04 −0.39 0.12 0.68 (0.47, 0.97) 0.03
> 10.9 −0.89 0.09 0.41 (0.26, 0.65) < 0.001 −0.83 0.10 0.44 (0.28, 0.69) < 0.001
§UF volume, ml
< 1,000 1 1
≥ 1,000 −0.38 0.12 0.69 (0.49, 0.96) 0.03 −0.63 0.10 0.53 (0.37, 0.76) 0.00
μSBP, mmHg
< 140 1 1
≥ 140 −0.36 0.11 0.70 (0.51, 0.95) 0.02 −0.37 0.11 0.69 (0.51, 0.94) 0.02
Diabetes
Yes 0.36 0.26 1.43 (1.00, 2.03) 0.05 0.36 0.28 1.43 (0.98, 2.09) 0.06
No 1 1
Ӕ Standard Error, ᴚ Hazards Ratio, θ Confidence Interval, £ Body mass index, § Ultra-filtration, μ Systolic blood pressure, Conversion factors for units: serum
albumin in g/dL to g/L, ×10; hemoglobin in mg/dL to g/L, ×10.
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Kidney Disease Outcome Quality Initiative (KDOQI)
guideline [25]. Two randomized controlled trials [13,14]
have assessed the effects of tKt/V targets advocated by
the previous KDOQI guideline. The ADEMEX study
[13] compared the modified prescriptions to achieve a
target tCrcl of > 60 L/week/1.73 m2 with the four 2-L
daily exchanges of standard PD solution. They found no
significant differences in patient survival, technique sur-
vival, and quality of life between intervention and con-
trol groups. The Hong Kong study [14] which hadrandomized patients to 3 different tKt/V targets also
showed negative results.
Some studies [7,11,12] considered two or more indi-
ces of small solute clearance simultaneously in the re-
gression models. Since tKt/V was the sum of pKt/V plus
rKt/V, the two variables were highly correlated with the
estimated correlation coefficient of 0.388 (p-value < 0.001).
Although including them simultaneously in the same
model did not cause much multicolinearity as we were
aware, adding tKt/V in the model which already
contained rKt/V did not improve the explanation of
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(p = 0.82).
Increased serum albumin, hemoglobin, UF volume,
and SBP > 140 mmHg were also associated with a lower
risk of mortality. Interestingly, we found an inverse rela-
tionship between high SBP and risk of death. This find-
ing is consistent with recent findings in chronic kidney
disease/dialysis patients which suggested that low blood
pressure could be related to coexisting co-morbidities
such as heart failure, autonomic neuropathy, decreased
food intake, and worse nutritional status [26-29]. These
explanations may partly be attributable to these paradox-
ical findings, but the mechanism underlying this reverse
relationship is not clearly understood.
Our study has some strengths. Our study is a large
CAPD cohort with a median follow up time of nearly 2
years. We properly calibrated the rKt/V and tKt/V cut-
offs using ROC curve analysis. We considered study fac-
tors (i.e., rKt/V, tKt/V, and tCrcl ) and other observed
prognostic factors as time-varying co-variables in the
survival analyses, which should be better in explaining
disease prognosis than using only single measurements.
However, our study also has some limitations. First, the
study was not a randomized controlled trial and thus se-
lection and unobserved confounding biases could not be
avoided. Second, patients were only eligible if they had
data for tKt/V, which was about 10% of the entire co-
hort; so the representativeness of the whole CAPD
patients was limited. Third, we might face with survival
bias because of our inclusion criteria and differences of
characteristics of eligible versus ineligible patients. Our
results may be generalizable to patients who firstly
received CAPD with stable conditions, not patients with
critical conditions. The specific etiologies of death in-
cluding their prognostic factors were not evaluated due
to lack of information. Among eligible patients, some
variables were missing and thus multiple imputation
using regression analysis was applied to predict missing
values. Twenty imputations were applied taking into ac-
count the between-imputation variability.Conclusion
The cutoffs of 0.25 and 1.75 for rKt/V and tKt/V might
be targeted to prevent mortality in CAPD patients.
Serum albumin, hemoglobin, SBP, and UF volume are
also associated with mortality. However, our study may
face with selection and other unobserved confounders.
Further randomized control trial is required to confirm
these cutoffs.
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